Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 7/20 | 0.59 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 6/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ADH5 | P11766 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907521 | 0.91 | HTR5A (0.52) | HTR5AKMOMRGPRX4SRD5A1SRD5A2 | |
| SCHEMBL9907990 | 0.91 | HTR5A (0.52) | HTR5AMRGPRX4SRD5A1SRD5A2PLAU | |
| SCHEMBL9907733 | 0.90 | HTR5A (0.72) | HTR5AKMORORCPLAUADH5 | |
| SCHEMBL9907732 | 0.88 | SRD5A2 (0.49) | HTR5ASRD5A1SRD5A2PLAUKDM4C | |
| SCHEMBL9907769 | 0.88 | HTR5A (0.57) | HTR5ARORCPLAUADH5 | |
| SCHEMBL9907749 | 0.87 | HTR5A (0.56) | HTR5ARORCPLAUADH5 | |
| SCHEMBL9907681 | 0.86 | HTR5A (0.56) | HTR5ARORCPLAU | |
| SCHEMBL9907714 | 0.86 | HTR5A (0.55) | HTR5ARORC | |
| SCHEMBL9907750 | 0.85 | HTR5A (0.59) | HTR5APLAU | |
| SCHEMBL9907708 | 0.85 | KDM4C (0.47) | HTR5AMRGPRX4SRD5A1SRD5A2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885KMO 559/4885MRGPRX4 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.